Diminished Ovarian Reserve Medical Services in China

Diminished Ovarian Reserve (DOR) is a clinical condition characterized by a reduction in the quantity and/or quality of ovarian follicles, leading to impaired reproductive potential. It reflects an early decline in ovarian function—distinct from natural menopause—but often precedes premature ovarian insufficiency (POI). Pathogenically, DOR arises from accelerated follicular atresia, genetic abnormalities (e.g., FMR1 premutation, Turner syndrome mosaicism), iatrogenic causes (chemotherapy, pelvic radiation, or ovarian surgery), autoimmune dysfunction, or idiopathic mechanisms involving mitochondrial dysfunction, oxidative stress, and dysregulated apoptosis in granulosa cells. Unlike polycystic ovary syndrome (PCOS) or hypothalamic amenorrhea, DOR is primarily a quantitative and qualitative biomarker issue—evidenced by elevated basal FSH (>10 IU/L), low anti-Müllerian hormone (AMH < 1.1 ng/mL), and reduced antral follicle count (AFC < 5–7 per ovary)—rather than a hormonal imbalance disorder. Epidemiologically, DOR affects approximately 10–15% of women seeking fertility care globally; prevalence rises sharply after age 35, with up to 30% of women aged 40+ exhibiting biochemical signs of diminished reserve. Risk factors include advanced maternal age (strongest modifiable risk), smoking, prior gonadotoxic exposure, endometriosis (especially stage III/IV with ovarian involvement), autoimmune thyroiditis, and family history of early menopause. Importantly, DOR is not synonymous with infertility—it indicates reduced odds per cycle but does not preclude spontaneous conception, particularly in younger patients with preserved oocyte quality. Quality of life impact extends beyond fertility concerns: women with DOR frequently report heightened anxiety, depression, grief over perceived biological time loss, marital strain, and diminished self-worth tied to reproductive identity. Many experience diagnostic delays due to normal menstrual cyclicity masking underlying reserve decline, resulting in late-stage emotional and financial burden. Early recognition via AMH/AFC/FSH screening—especially before elective fertility preservation—is critical for personalized counseling, timely intervention (e.g., IVF with PGT-A), and psychosocial support integration. Multidisciplinary management in reproductive endocrinology emphasizes realistic expectation-setting, shared decision-making, and holistic care addressing both physiological and existential dimensions of reproductive aging.

Diminished Ovarian Reserve (DOR) is a clinical diagnosis characterized by reduced quantity and/or quality of ovarian follicles, leading to impaired reproductive potential. It is commonly identified by elevated follicle-stimulating hormone (FSH) levels (>10 IU/L on cycle days 2–4), low anti-Müllerian hormone (AMH) (<1.1 ng/mL), and/or diminished antral follicle count (AFC <5–7 per ovary) on transvaginal ultrasound. DOR may occur in women of any age but is particularly relevant in those seeking fertility preservation or undergoing assisted reproductive technology (ART). Management is individualized, multifactorial, and aims to optimize natural conception, enhance response to ovarian stimulation, preserve remaining ovarian function, and support psychological well-being.

Conservative treatment forms the cornerstone of early or mild DOR management. Lifestyle modification is evidence-informed: sustained weight normalization (BMI 18.5–24.9 kg/m²), smoking cessation, and avoidance of excessive alcohol and caffeine significantly improve ovarian microenvironment and oocyte mitochondrial function. Nutritional interventions include antioxidant-rich diets (e.g., Mediterranean pattern), supplementation with coenzyme Q10 (200–600 mg/day), vitamin D (if deficient; target serum 25(OH)D >30 ng/mL), and omega-3 fatty acids—each shown in randomized trials to modestly improve AFC, AMH stability, and embryo quality. Mindfulness-based stress reduction and cognitive behavioral therapy are recommended adjuncts, as chronic hypothalamic-pituitary-adrenal axis dysregulation correlates with accelerated follicular atresia. Timed intercourse guided by urinary luteinizing hormone (LH) surge detection remains appropriate for patients with regular cycles and preserved tubal patency, though pregnancy rates decline markedly with AMH <0.5 ng/mL.

Pharmacologic strategies focus on optimizing follicular recruitment and endometrial receptivity. First-line ART protocols include mild ovarian stimulation using clomiphene citrate (50–100 mg/day, days 3–7) or letrozole (2.5–7.5 mg/day, days 3–7), often combined with low-dose gonadotropins (e.g., 75–150 IU recombinant FSH). Antagonist protocols with GnRH antagonist cotreatment minimize premature luteinization and are preferred over long agonist regimens in DOR due to lower cancellation rates. Adjuvant therapies under active investigation include dehydroepiandrosterone (DHEA) supplementation (25 mg three times daily for ≥4 months), which has demonstrated improved AFC, AMH, and live birth rates in meta-analyses—though its use requires baseline androgen panel assessment and contraindication screening (e.g., PCOS, adrenal hyperplasia). Growth hormone (GH) co-treatment (0.3–0.6 mg/day subcutaneously from stimulation day 1) enhances granulosa cell IGF-1 signaling and is increasingly adopted in poor responders, with RCTs reporting increased oocyte yield and blastocyst formation. Melatonin (3 mg nightly) may reduce oxidative damage in maturing oocytes. All pharmacotherapy must be administered under strict reproductive endocrinology supervision, with serial ultrasound and estradiol monitoring to prevent overstimulation or cycle cancellation.

Surgical intervention has no established role in reversing DOR itself, as follicular depletion is irreversible. However, laparoscopic ovarian drilling may be considered in select DOR patients with concomitant polycystic ovary morphology and hyperandrogenism unresponsive to medical therapy—though this is rare and carries risk of iatrogenic ovarian damage. More investigational approaches include ovarian tissue cryopreservation (primarily for oncology patients pre-chemotherapy) and in vitro activation (IVA) of residual primordial follicles via fragmentation and PI3K/Akt pathway modulation; these remain experimental and are not standard-of-care outside clinical trials. Ovarian transplantation is not clinically viable for DOR due to insufficient donor tissue and immunologic barriers.

China offers distinct advantages in DOR management within its reproductive medicine specialty. The country hosts over 500 accredited ART centers, many integrated within tier-1 university hospitals (e.g., Peking University Third Hospital, Shanghai Jiao Tong University Affiliated Renji Hospital), ensuring standardized protocols aligned with both Chinese Medical Association guidelines and international best practices (ESHRE/ASRM). Advanced diagnostics—including high-resolution 3D AFC quantification, automated AMH immunoassays, and next-generation sequencing for genetic causes (e.g., FMR1 premutation screening)—are widely accessible and cost-effective. Traditional Chinese Medicine (TCM) integration is uniquely robust: licensed TCM gynecologists routinely prescribe evidence-informed herbal formulas (e.g., Zishen Yutai Wan or Bushen Huoxue decoctions) alongside ART, with prospective cohort studies demonstrating improved implantation rates and reduced miscarriage risk—likely via modulation of uterine blood flow, NK-cell activity, and oxidative stress. Furthermore, China’s national ART insurance coverage expansion (as of 2023 in 26 provinces) significantly reduces financial burden, enabling multi-cycle attempts critical for DOR patients. Regulatory oversight by the National Health Commission ensures rigorous laboratory accreditation (ISO 15189), stringent embryologist certification, and mandatory outcome reporting—contributing to consistently high cumulative live birth rates per retrieval (up to 42% in optimized DOR cohorts aged <38).

Recovery and long-term follow-up emphasize holistic continuity of care. Patients should undergo biannual endocrine evaluation (FSH, AMH, estradiol, thyroid panel, lipid profile) to monitor progression toward menopause and assess cardiovascular/metabolic risk. Bone mineral density screening is advised if amenorrhea persists >6 months. Emotional resilience is supported through structured peer networks and psychologist-led fertility counseling embedded in most major centers. For those pursuing ART, elective single-embryo transfer (eSET) is strongly encouraged to mitigate multiple gestation risks, especially given higher baseline obstetric comorbidity in DOR. Post-retrieval, pelvic rest for 48 hours and hydration are recommended; however, routine bed rest is discouraged. Patients who discontinue ART should receive personalized menopause transition guidance, including non-hormonal symptom management and timely initiation of menopausal hormone therapy (MHT) if indicated—always weighing individual thrombotic and breast cancer risk profiles. Ultimately, successful DOR management transcends technical intervention: it requires empathetic communication, realistic expectation setting, shared decision-making, and lifelong reproductive health stewardship.